Impact of n − 3 fatty acids on endothelial function: results from human interventions studies

PURPOSE OF REVIEWDysfunction of the endothelium plays an integral role in atherogenesis. This review summarizes recent findings on the effects of marine [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and plant [alpha-linolenic acids (ALA)] n − 3 polyunsaturated fatty acids (PUFAs) on endo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current opinion in clinical nutrition and metabolic care 2011-03, Vol.14 (2), p.121-131
Hauptverfasser: Egert, Sarah, Stehle, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 131
container_issue 2
container_start_page 121
container_title Current opinion in clinical nutrition and metabolic care
container_volume 14
creator Egert, Sarah
Stehle, Peter
description PURPOSE OF REVIEWDysfunction of the endothelium plays an integral role in atherogenesis. This review summarizes recent findings on the effects of marine [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and plant [alpha-linolenic acids (ALA)] n − 3 polyunsaturated fatty acids (PUFAs) on endothelial function in healthy individuals and in patients with cardiovascular disease (CVD) risk factors or manifest CVD. RECENT FINDINGSWe identified 33 intervention trials investigating the effects of n − 3 PUFA on fasting and/or postprandial endothelial function. In healthy individuals regular supplementation of EPA/DHA or ALA shows inconsistent results on endothelial function, whereas markers of endothelial function seem to be improved in overweight dyslipidaemic patients and type 2 diabetics. Conflicting results are observed in CVD patients. Reasons for discrepancies between the study results include the health status and age of participants, duration of supplementation, dose and fatty acid composition of the administered n − 3 PUFAs as well as methods used to assess endothelial function. SUMMARYIn individuals with CVD risk factors including overweight, dyslipidemia and type 2 diabetes n − 3 PUFAs may improve endothelial function. However, the evidence for a clinical efficacy is not strong enough to make final recommendations with respect to a specific dose and the duration of supplementation.
doi_str_mv 10.1097/MCO.0b013e3283439622
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_851477329</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>851477329</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4212-a94d4c474dff819870dd6dd7ed58f8a40b3e794a334d925c3b8746f00a3eeb1f3</originalsourceid><addsrcrecordid>eNp9kDlOBDEQRS0EYr8BQs6IGrz1YjI0YpNAJBBb7nZZ0-C2B9vNiBsQc0ROQqMBAgKiquD9X6WH0AElx5TI-uR2dndMWkI5cNZwwWXF2BrapqLmRVVSuT7tvOIFlSXZQjspPRJCmSR8E20xykpWlWwbqethobuMg8Uef7y9Y46tzvkV6643CQePwZuQ5-B67bAdfZf74E9xhDS6nLCNYcDzcdAe9z5DfAH_BSSc8mh6SHtow2qXYP977qKHi_P72VVxc3d5PTu7KToxPVNoKYzoRC2MtQ2VTU2MqYypwZSNbbQgLYdaCs25MJKVHW-bWlSWEM0BWmr5Ljpa9S5ieB4hZTX0qQPntIcwJtWUk5iaMzmRYkV2MaQUwapF7AcdXxUl6susmsyqv2an2OH3gbEdwPyGflROQLMClsFNItKTG5cQ1Ry0y_P_uz8BzAiH5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>851477329</pqid></control><display><type>article</type><title>Impact of n − 3 fatty acids on endothelial function: results from human interventions studies</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Egert, Sarah ; Stehle, Peter</creator><creatorcontrib>Egert, Sarah ; Stehle, Peter</creatorcontrib><description>PURPOSE OF REVIEWDysfunction of the endothelium plays an integral role in atherogenesis. This review summarizes recent findings on the effects of marine [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and plant [alpha-linolenic acids (ALA)] n − 3 polyunsaturated fatty acids (PUFAs) on endothelial function in healthy individuals and in patients with cardiovascular disease (CVD) risk factors or manifest CVD. RECENT FINDINGSWe identified 33 intervention trials investigating the effects of n − 3 PUFA on fasting and/or postprandial endothelial function. In healthy individuals regular supplementation of EPA/DHA or ALA shows inconsistent results on endothelial function, whereas markers of endothelial function seem to be improved in overweight dyslipidaemic patients and type 2 diabetics. Conflicting results are observed in CVD patients. Reasons for discrepancies between the study results include the health status and age of participants, duration of supplementation, dose and fatty acid composition of the administered n − 3 PUFAs as well as methods used to assess endothelial function. SUMMARYIn individuals with CVD risk factors including overweight, dyslipidemia and type 2 diabetes n − 3 PUFAs may improve endothelial function. However, the evidence for a clinical efficacy is not strong enough to make final recommendations with respect to a specific dose and the duration of supplementation.</description><identifier>ISSN: 1363-1950</identifier><identifier>EISSN: 1473-6519</identifier><identifier>DOI: 10.1097/MCO.0b013e3283439622</identifier><identifier>PMID: 21252652</identifier><language>eng</language><publisher>England: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>alpha-Linolenic Acid - administration &amp; dosage ; alpha-Linolenic Acid - pharmacology ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - metabolism ; Dietary Supplements ; Docosahexaenoic Acids - administration &amp; dosage ; Docosahexaenoic Acids - pharmacology ; Eicosapentaenoic Acid - administration &amp; dosage ; Eicosapentaenoic Acid - pharmacology ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiology ; Fatty Acids, Omega-3 - administration &amp; dosage ; Fatty Acids, Omega-3 - pharmacology ; Fatty Acids, Omega-3 - therapeutic use ; Humans ; Risk Factors</subject><ispartof>Current opinion in clinical nutrition and metabolic care, 2011-03, Vol.14 (2), p.121-131</ispartof><rights>2011 Lippincott Williams &amp; Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4212-a94d4c474dff819870dd6dd7ed58f8a40b3e794a334d925c3b8746f00a3eeb1f3</citedby><cites>FETCH-LOGICAL-c4212-a94d4c474dff819870dd6dd7ed58f8a40b3e794a334d925c3b8746f00a3eeb1f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21252652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Egert, Sarah</creatorcontrib><creatorcontrib>Stehle, Peter</creatorcontrib><title>Impact of n − 3 fatty acids on endothelial function: results from human interventions studies</title><title>Current opinion in clinical nutrition and metabolic care</title><addtitle>Curr Opin Clin Nutr Metab Care</addtitle><description>PURPOSE OF REVIEWDysfunction of the endothelium plays an integral role in atherogenesis. This review summarizes recent findings on the effects of marine [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and plant [alpha-linolenic acids (ALA)] n − 3 polyunsaturated fatty acids (PUFAs) on endothelial function in healthy individuals and in patients with cardiovascular disease (CVD) risk factors or manifest CVD. RECENT FINDINGSWe identified 33 intervention trials investigating the effects of n − 3 PUFA on fasting and/or postprandial endothelial function. In healthy individuals regular supplementation of EPA/DHA or ALA shows inconsistent results on endothelial function, whereas markers of endothelial function seem to be improved in overweight dyslipidaemic patients and type 2 diabetics. Conflicting results are observed in CVD patients. Reasons for discrepancies between the study results include the health status and age of participants, duration of supplementation, dose and fatty acid composition of the administered n − 3 PUFAs as well as methods used to assess endothelial function. SUMMARYIn individuals with CVD risk factors including overweight, dyslipidemia and type 2 diabetes n − 3 PUFAs may improve endothelial function. However, the evidence for a clinical efficacy is not strong enough to make final recommendations with respect to a specific dose and the duration of supplementation.</description><subject>alpha-Linolenic Acid - administration &amp; dosage</subject><subject>alpha-Linolenic Acid - pharmacology</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - metabolism</subject><subject>Dietary Supplements</subject><subject>Docosahexaenoic Acids - administration &amp; dosage</subject><subject>Docosahexaenoic Acids - pharmacology</subject><subject>Eicosapentaenoic Acid - administration &amp; dosage</subject><subject>Eicosapentaenoic Acid - pharmacology</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiology</subject><subject>Fatty Acids, Omega-3 - administration &amp; dosage</subject><subject>Fatty Acids, Omega-3 - pharmacology</subject><subject>Fatty Acids, Omega-3 - therapeutic use</subject><subject>Humans</subject><subject>Risk Factors</subject><issn>1363-1950</issn><issn>1473-6519</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDlOBDEQRS0EYr8BQs6IGrz1YjI0YpNAJBBb7nZZ0-C2B9vNiBsQc0ROQqMBAgKiquD9X6WH0AElx5TI-uR2dndMWkI5cNZwwWXF2BrapqLmRVVSuT7tvOIFlSXZQjspPRJCmSR8E20xykpWlWwbqethobuMg8Uef7y9Y46tzvkV6643CQePwZuQ5-B67bAdfZf74E9xhDS6nLCNYcDzcdAe9z5DfAH_BSSc8mh6SHtow2qXYP977qKHi_P72VVxc3d5PTu7KToxPVNoKYzoRC2MtQ2VTU2MqYypwZSNbbQgLYdaCs25MJKVHW-bWlSWEM0BWmr5Ljpa9S5ieB4hZTX0qQPntIcwJtWUk5iaMzmRYkV2MaQUwapF7AcdXxUl6susmsyqv2an2OH3gbEdwPyGflROQLMClsFNItKTG5cQ1Ry0y_P_uz8BzAiH5g</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Egert, Sarah</creator><creator>Stehle, Peter</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201103</creationdate><title>Impact of n − 3 fatty acids on endothelial function: results from human interventions studies</title><author>Egert, Sarah ; Stehle, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4212-a94d4c474dff819870dd6dd7ed58f8a40b3e794a334d925c3b8746f00a3eeb1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>alpha-Linolenic Acid - administration &amp; dosage</topic><topic>alpha-Linolenic Acid - pharmacology</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - metabolism</topic><topic>Dietary Supplements</topic><topic>Docosahexaenoic Acids - administration &amp; dosage</topic><topic>Docosahexaenoic Acids - pharmacology</topic><topic>Eicosapentaenoic Acid - administration &amp; dosage</topic><topic>Eicosapentaenoic Acid - pharmacology</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiology</topic><topic>Fatty Acids, Omega-3 - administration &amp; dosage</topic><topic>Fatty Acids, Omega-3 - pharmacology</topic><topic>Fatty Acids, Omega-3 - therapeutic use</topic><topic>Humans</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egert, Sarah</creatorcontrib><creatorcontrib>Stehle, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in clinical nutrition and metabolic care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egert, Sarah</au><au>Stehle, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of n − 3 fatty acids on endothelial function: results from human interventions studies</atitle><jtitle>Current opinion in clinical nutrition and metabolic care</jtitle><addtitle>Curr Opin Clin Nutr Metab Care</addtitle><date>2011-03</date><risdate>2011</risdate><volume>14</volume><issue>2</issue><spage>121</spage><epage>131</epage><pages>121-131</pages><issn>1363-1950</issn><eissn>1473-6519</eissn><abstract>PURPOSE OF REVIEWDysfunction of the endothelium plays an integral role in atherogenesis. This review summarizes recent findings on the effects of marine [eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and plant [alpha-linolenic acids (ALA)] n − 3 polyunsaturated fatty acids (PUFAs) on endothelial function in healthy individuals and in patients with cardiovascular disease (CVD) risk factors or manifest CVD. RECENT FINDINGSWe identified 33 intervention trials investigating the effects of n − 3 PUFA on fasting and/or postprandial endothelial function. In healthy individuals regular supplementation of EPA/DHA or ALA shows inconsistent results on endothelial function, whereas markers of endothelial function seem to be improved in overweight dyslipidaemic patients and type 2 diabetics. Conflicting results are observed in CVD patients. Reasons for discrepancies between the study results include the health status and age of participants, duration of supplementation, dose and fatty acid composition of the administered n − 3 PUFAs as well as methods used to assess endothelial function. SUMMARYIn individuals with CVD risk factors including overweight, dyslipidemia and type 2 diabetes n − 3 PUFAs may improve endothelial function. However, the evidence for a clinical efficacy is not strong enough to make final recommendations with respect to a specific dose and the duration of supplementation.</abstract><cop>England</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>21252652</pmid><doi>10.1097/MCO.0b013e3283439622</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1363-1950
ispartof Current opinion in clinical nutrition and metabolic care, 2011-03, Vol.14 (2), p.121-131
issn 1363-1950
1473-6519
language eng
recordid cdi_proquest_miscellaneous_851477329
source MEDLINE; Journals@Ovid Complete
subjects alpha-Linolenic Acid - administration & dosage
alpha-Linolenic Acid - pharmacology
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - metabolism
Dietary Supplements
Docosahexaenoic Acids - administration & dosage
Docosahexaenoic Acids - pharmacology
Eicosapentaenoic Acid - administration & dosage
Eicosapentaenoic Acid - pharmacology
Endothelium, Vascular - drug effects
Endothelium, Vascular - physiology
Fatty Acids, Omega-3 - administration & dosage
Fatty Acids, Omega-3 - pharmacology
Fatty Acids, Omega-3 - therapeutic use
Humans
Risk Factors
title Impact of n − 3 fatty acids on endothelial function: results from human interventions studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T12%3A17%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20n%20%E2%88%92%203%20fatty%20acids%20on%20endothelial%20function:%20results%20from%20human%20interventions%20studies&rft.jtitle=Current%20opinion%20in%20clinical%20nutrition%20and%20metabolic%20care&rft.au=Egert,%20Sarah&rft.date=2011-03&rft.volume=14&rft.issue=2&rft.spage=121&rft.epage=131&rft.pages=121-131&rft.issn=1363-1950&rft.eissn=1473-6519&rft_id=info:doi/10.1097/MCO.0b013e3283439622&rft_dat=%3Cproquest_cross%3E851477329%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=851477329&rft_id=info:pmid/21252652&rfr_iscdi=true